Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:23:33.423Z.
Calculation as of: 2026-10-06T18:23:33.423Z.
Quote observation: 2026-10-06T18:20:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3fd66fa07f89ff8c2236b8eda0ba832ed38a6b1a46891be7cbf8760d0061f77
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$524770.00
EV/Sales Ratio
N/A
TTM Avg
1.41x
3Y Avg
1.41x
5Y Avg
1.41x
Market Cap
$552749.00
EV/Sales Ratio
0.95x
TTM Avg
22.73x
3Y Avg
233.34x
5Y Avg
409.95x
Market Cap
$380715.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$814312.00
EV/Sales Ratio
N/A
TTM Avg
18336.38x
3Y Avg
32990.15x
5Y Avg
90979.77x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $490141.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $524770.00 | N/A | 1.41x | 1.41x | 1.41x |
| HCW Biologics Inc. (HCWB)vs › | $552749.00 | 0.95x | 22.73x | 233.34x | 409.95x |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $667682.00 | 0.67x | 1.27x | 1.27x | 1.27x |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $814312.00 | N/A | 18336.38x | 32990.15x | 90979.77x |
| Ridgetech, Inc. (RDGT)vs › | $812262.00 | N/A | 0.20x | 0.19x | 0.16x |
| Decoy Therapeutics Inc. (DCOY)vs › | $838967.00 | N/A | 78.84x | 47.25x | 902.93x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
